Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Healthcare information technology (HCIT) solutions provider Cerner Corp ( CERN - Analyst Report ) and medical technology company CareFusion ( CFN - Snapshot Report ) recently announced the implementation of interconnected systems at the well-regarded teaching and research hospital Penn State Milton S. Hershey Medical Center.
The systems which share data will improve medication management at the Magnet organization, Penn State Hershey. The latest offering by CareFusion and Cerner allows data sharing and assimilation of clinical information between the automated medication dispensing technology of CareFusion’s Pyxis MedStation 4000 system and the Cerner Millennium electronic health record (EHR) system, via Cerner's CareAware iBus integrated device connectivity architecture.
The features of this joint offering will improve standards of care by reducing time and enhancing efficiency of medication dispensing. The integration of these leading technologies underlines the strategic initiatives of CareFusion to reform medication management.
Earlier in 2010, CareFusion and Cerner inked a strategic agreement to develop solutions to improve quality of care via interoperability and system connectivity, on the back of amalgamation of the pioneering technologies. The integration allowed CareFusion to unify its Pyxis medication technologies, Alaris infusion pumps and Ventilation systems with Cerner’s CareAware iBus and Cerner Millennium.
Cerner continues to extend its existing broad footprint in the domestic market. Such integration is expected to allow the company to gain hospital deals. Cerner remains the trend setter among pure-play, publicly traded healthcare IT (HCIT) vendors. Its second quarter revenues climbed 22% year over year to $637.4 million on the back of Support, Maintenance and Services (up 19.9% to $426 million), robust System sales (up 24.2% to $195.3 million) and higher revenues from Reimbursed Travel (up 36.3% to about $16.0 million).
We believe long-term investors may consider Cerner, which serves a sizeable installed hospital base. It requires composite clinically-focused applications complying with ‘meaningful use’ requirements, reimbursement problems and complex coding challenges. The company has long-standing, integrated and seamless solutions for both inpatient and ambulatory settings.
On the negative side, the federal Stimulus program will gradually wind down. Cerner faces stiff competition from established HCIT players, such as Athenahealth ( ATHN - Analyst Report ) , Allscripts Healthcare ( MDRX - Analyst Report ) and Quality Systems ( QSII - Analyst Report ) and many others in a crowded field. The company is developing multiple growth drivers which will ensure its future growth.
We have a long-term ‘Neutral’ recommendation on Cerner. The stock currently retains a Zacks #3 Rank, which translates into a short-term Hold rating.
Read the full Analyst Report on CERN
Read the full Snapshot Report on CFN
Read the full Analyst Report on ATHN
Read the full Analyst Report on MDRX
Read the full Analyst Report on QSII